Cargando…
Natural Killer Cells: Development, Maturation, and Clinical Utilization
Natural killer (NK) cells are the predominant innate lymphocyte subsets that mediate anti-tumor and anti-viral responses, and therefore possess promising clinical utilization. NK cells do not express polymorphic clonotypic receptors and utilize inhibitory receptors (killer immunoglobulin-like recept...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099181/ https://www.ncbi.nlm.nih.gov/pubmed/30150991 http://dx.doi.org/10.3389/fimmu.2018.01869 |
_version_ | 1783348608574160896 |
---|---|
author | Abel, Alex M. Yang, Chao Thakar, Monica S. Malarkannan, Subramaniam |
author_facet | Abel, Alex M. Yang, Chao Thakar, Monica S. Malarkannan, Subramaniam |
author_sort | Abel, Alex M. |
collection | PubMed |
description | Natural killer (NK) cells are the predominant innate lymphocyte subsets that mediate anti-tumor and anti-viral responses, and therefore possess promising clinical utilization. NK cells do not express polymorphic clonotypic receptors and utilize inhibitory receptors (killer immunoglobulin-like receptor and Ly49) to develop, mature, and recognize “self” from “non-self.” The essential roles of common gamma cytokines such as interleukin (IL)-2, IL-7, and IL-15 in the commitment and development of NK cells are well established. However, the critical functions of pro-inflammatory cytokines IL-12, IL-18, IL-27, and IL-35 in the transcriptional-priming of NK cells are only starting to emerge. Recent studies have highlighted multiple shared characteristics between NK cells the adaptive immune lymphocytes. NK cells utilize unique signaling pathways that offer exclusive ways to genetically manipulate to improve their effector functions. Here, we summarize the recent advances made in the understanding of how NK cells develop, mature, and their potential translational use in the clinic. |
format | Online Article Text |
id | pubmed-6099181 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-60991812018-08-27 Natural Killer Cells: Development, Maturation, and Clinical Utilization Abel, Alex M. Yang, Chao Thakar, Monica S. Malarkannan, Subramaniam Front Immunol Immunology Natural killer (NK) cells are the predominant innate lymphocyte subsets that mediate anti-tumor and anti-viral responses, and therefore possess promising clinical utilization. NK cells do not express polymorphic clonotypic receptors and utilize inhibitory receptors (killer immunoglobulin-like receptor and Ly49) to develop, mature, and recognize “self” from “non-self.” The essential roles of common gamma cytokines such as interleukin (IL)-2, IL-7, and IL-15 in the commitment and development of NK cells are well established. However, the critical functions of pro-inflammatory cytokines IL-12, IL-18, IL-27, and IL-35 in the transcriptional-priming of NK cells are only starting to emerge. Recent studies have highlighted multiple shared characteristics between NK cells the adaptive immune lymphocytes. NK cells utilize unique signaling pathways that offer exclusive ways to genetically manipulate to improve their effector functions. Here, we summarize the recent advances made in the understanding of how NK cells develop, mature, and their potential translational use in the clinic. Frontiers Media S.A. 2018-08-13 /pmc/articles/PMC6099181/ /pubmed/30150991 http://dx.doi.org/10.3389/fimmu.2018.01869 Text en Copyright © 2018 Abel, Yang, Thakar and Malarkannan. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Abel, Alex M. Yang, Chao Thakar, Monica S. Malarkannan, Subramaniam Natural Killer Cells: Development, Maturation, and Clinical Utilization |
title | Natural Killer Cells: Development, Maturation, and Clinical Utilization |
title_full | Natural Killer Cells: Development, Maturation, and Clinical Utilization |
title_fullStr | Natural Killer Cells: Development, Maturation, and Clinical Utilization |
title_full_unstemmed | Natural Killer Cells: Development, Maturation, and Clinical Utilization |
title_short | Natural Killer Cells: Development, Maturation, and Clinical Utilization |
title_sort | natural killer cells: development, maturation, and clinical utilization |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099181/ https://www.ncbi.nlm.nih.gov/pubmed/30150991 http://dx.doi.org/10.3389/fimmu.2018.01869 |
work_keys_str_mv | AT abelalexm naturalkillercellsdevelopmentmaturationandclinicalutilization AT yangchao naturalkillercellsdevelopmentmaturationandclinicalutilization AT thakarmonicas naturalkillercellsdevelopmentmaturationandclinicalutilization AT malarkannansubramaniam naturalkillercellsdevelopmentmaturationandclinicalutilization |